Clovis Oncology Inc (CLVS)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

5500 FLATIRON PARKWAY BOULDER, CO 80301

Clovis Oncology, Inc. develops and commercializes anti-cancer pharmaceutical drugs. The company develops CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine, which is in Phase III clinical trials for first-line treatment of metastatic pancreatic cancer; Phase II clinical trials for second-line treatment of metastatic pancreatic cancer; and preclinical trials for solid tumors. Its products also include CO-1686, a small molecule epidermal growth factor receptor, which is in preclinical trials for the treatment of non-small cell lung cancer; and CO-338, a small molecule PARP inhibitor, which is in Phase II clinical trials for the adjuvant treatment of hereditary, or germ-line, BRCA mutant, and triple-negative breast cancer, as well as Phase I clinical trials for the treatment of solid tumors. The company intends to sell its products through distributors in the United States, Europe, and internationally. Clovis Oncology, Inc. was founded in 2009 and is based in Boulder, Colorado.

Data based on most recent fiscal year report
Market Cap2.461 Billion Shares Outstanding49.02 Million Avg Volume2.62 Million
1-Yr BETA vs S&P TR Current Ratio7.69 Quick Ratio7.35
View SEC Filings from CLVS instead.
Q2 2019 All Institutions Hedge Funds 1
To trade CLVS now:
Filers who had this stock in their top 10: 1 0 (0.0%)
13F Filers holding this stock: 163 35 (3.62%)
Aggregate 13F shares on 06/30/2019: 50.094 Million 20.305 Million
Aggregate 13F shares on 03/31/2019: 49.395 Million 23.569 Million
Percent change: 1.41% -13.85%
Funds creating new positions: 24 8
Funds Adding to an existing position: 70 17
Funds closing out their position: 41 8
Funds reducing their position: 39 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CLVS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

107.8 Thousand total shares from 14 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

51.7 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ROLFE LINDSEY

  • Director
0 2019-08-22 9

ATWOOD BRIAN G

  • Director
153,294 2019-08-20 3

SPICKSCHEN THORLEF

  • Director
58,176 2019-08-16 5

BLAIR JAMES C

  • Director
63,544 2019-08-16 5

MAHAFFY PATRICK J PRESIDENT AND CEO

  • Officer
  • Director
970,787 2019-08-16 2

KAMDAR KIM P.

  • Director
27,148 2019-08-06 0

KLINGENSTEIN PAUL H

  • Director
711,160 2019-07-29 3

BARRIS PETER J

  • 10% Owner
4,186,243 2019-07-22 0

BASKETT FOREST

  • 10% Owner
4,186,243 2019-07-22 0

SANDELL SCOTT D

  • 10% Owner
4,186,243 2019-07-22 0

MOTT DAVID M

  • 10% Owner
4,186,243 2019-07-22 0

GRAHAM GINGER L

  • Director
53,119 2019-07-01 2

IVERS-READ GILLIAN C SEE REMARKS

  • Officer
191,788 2019-06-20 9

HALAK BRIAN K

  • Director
0 2019-06-19 0

ALLEN ANDREW R

  • Director
0 2019-06-11 0

FAIR RICHARD A. PRESIDENT AND CEO

  • Officer
  • Director
0 2019-06-11 3

MCKINLEY EDWARD J

  • Director
0 2019-06-06 2

HOERTER STEVEN L.

  • Director
0 2019-06-06 0

FLAHERTY KEITH T.

  • Director
0 2019-06-06 2

AZELBY ROBERT

  • Director
0 2019-06-06 3

TREU JESSE I

  • Director
0 2019-06-04 0

MUEHL DANIEL W SEE REMARKS

  • Officer
8,220 2019-06-04 10

GROSS PAUL EDWARD SEE REMARKS

  • Officer
4,316 2019-06-04 4

BARRETT M JAMES

  • Director
0 2019-05-30 1

VITULLO NICOLE

  • Director
13,286 2019-05-29 0

MAST ERLE T

  • Director
0 2019-05-22 0

KRAMLICH C RICHARD

  • Director
0 2019-05-20 0

NEW ENTERPRISE ASSOCIATES 13 LP

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
0 2019-01-22 0

KERINS PATRICK J

  • 10% Owner
0 2019-01-22 0

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

VERSANT VENTURES IV, LLC

  • 10% Owner
5,174,727 2019-01-14 0

VISWANATHAN RAVI

  • 10% Owner
5,000,000 2018-10-17 0

FAIR RICHARD A.

FAIR RICHARD A.

  • Director
0 2018-10-11 3

HOOKS CORWIN DALE SEE REMARKS

  • Officer
5,349 2018-09-05 2

DOVEY BRIAN H

  • Director
3,722,188 2018-06-29 0

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
No longer subject to file 2017-11-06 0

NEW ENTERPRISE ASSOCIATES 13 LP

  • 10% Owner
No longer subject to file 2017-11-06 0

KOLLURI KRISHNA KITTU

  • 10% Owner
5,215,128 2016-12-19 0

WELLER HARRY R

  • 10% Owner
3,490,073 2016-10-31 0

DP VII ASSOCIATES LP

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

SCHOEMAKER KATHLEEN K

HALAK BRIAN K

  • 10% Owner
17,947 2015-08-18 0

DOMAIN PARTERS VII L P

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

SCHOEMAKER KATHLEEN K

HALAK BRIAN K

  • 10% Owner
1,052,328 2015-08-18 0

DRANT RYAN D

  • 10% Owner
7,489,485 2015-06-05 0

DOMAIN PARTERS VII L P

  • 10% Owner
No longer subject to file 2014-03-19 0

SCHOEMAKER KATHLEEN K

  • 10% Owner
No longer subject to file 2014-03-19 0

DP VII ASSOCIATES LP

  • 10% Owner
No longer subject to file 2014-03-19 0

DOMAIN ASSOCIATES

  • 10% Owner
No longer subject to file 2014-03-19 0

REED JOHN C

  • Director
0 2012-09-04 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

ATWOOD BRIAN G - Director

2019-08-20 M 25,862 d 0 153,294.00 direct

ATWOOD BRIAN G - Director

2019-08-20 M 25,862 $0.29 a 25,862 153,294.00 direct

BLAIR JAMES C - Director by wife

2019-08-20 P 20,000 $5.97 a 20,000 63,544.00 indirect

BLAIR JAMES C - Director

2019-08-16 P 20,000 $5.70 a 33,439 63,544.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 11,053 $5.59 a 957,860 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 6,400 $5.61 a 931,793 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 400 $5.58 a 919,587 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 5,827 $5.60 a 968,787 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 3,700 $5.59 a 946,807 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 2,100 $5.61 a 925,393 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 400 $5.56 a 919,187 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 5,100 $5.60 a 962,960 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 11,314 $5.58 a 943,107 970,787.00 direct

MAHAFFY PATRICK J - Director - Officer PRESIDENT AND CEO

2019-08-16 P 3,706 $5.57 a 923,293 970,787.00 direct

SPICKSCHEN THORLEF - Director

2019-08-16 P 8,600 $5.67 a 58,176 58,176.00 direct

SPICKSCHEN THORLEF - Director

2019-08-14 P 9,200 $5.46 a 49,576 49,576.00 direct

KLINGENSTEIN PAUL H - Director

2019-07-29 M 25,862 $0.29 a 59,327 711,160.00 direct

KLINGENSTEIN PAUL H - Director

2019-07-29 M 25,862 d 0 711,160.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments